Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 11/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.59 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10860157 | 0.98 | HPGD (0.68) | HPGDSIGMAR1CYP2D6CXCR4MEN1 | |
| Hydrochloric Acid SCHEMBL27569479 | 0.98 | HPGD (0.68) | HPGDSIGMAR1CYP2D6CXCR4MEN1 | |
| Hydrochloric Acid SCHEMBL27862467 | 0.98 | HPGD (0.68) | HPGDSIGMAR1CYP2D6CXCR4MEN1 | |
| SCHEMBL4022095 | 0.93 | CXCR4 (0.72) | HPGDSIGMAR1CYP2D6CXCR4MEN1 | |
| Pyridine SCHEMBL28301244 | 0.85 | SIGMAR1 (0.79) | HPGDSIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL28269086 | 0.85 | LSS (0.66) | HPGDSIGMAR1CYP2D6MEN1CCR2 | |
| Dalfampridine SCHEMBL28192260 | 0.84 | SIGMAR1 (0.70) | HPGDSIGMAR1CYP2D6CXCR4MEN1 | |
| Hydrochloric Acid SCHEMBL5573232 | 0.83 | CXCR4 (0.78) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL1259387 | 0.83 | CXCR4 (0.81) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL13050668 | 0.83 | HPGD (1.00) | HPGDCYP2D6MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684644-A | Eupatilin derivative containing piperazine structure and preparation method and application thereof | 南阳医学高等专科学校 | 2024-09-24 | — | — | CN | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-112191273-A | High-entropy coordination polymer catalyst for oxygen production by electrolyzing water and preparation method and application thereof | 中国科学技术大学 | 2021-01-08 | — | — | CN | claimed |
| CN-109438483-A | A kind of hybrid material preparation method of fluorescence temperature measuring appliance | 南京晓庄学院 | 2019-03-08 | — | — | CN | claimed |
| CN-109438484-A | A kind of hybrid material for temperature meter | 南京晓庄学院 | 2019-03-08 | — | — | CN | claimed |
| CN-109369688-A | A kind of application of material | 南京晓庄学院 | 2019-02-22 | — | — | CN | claimed |
| CN-108456217-B | Fluorescent temperature measurer hybrid material, preparation method and application | 南京晓庄学院 | 2019-01-25 | — | — | CN | claimed |
| CN-104507950-B | Thienopyrimidines | 拜耳医药股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| CN-101193867-A | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole libraries | OSI PHARM INC (US) | 2008-06-04 | — | — | CN | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260083728-A1 | COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA | OHIO STATE INNOVATIION FOUND (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3946349-B1 | SR-1903 FOR THE TREATMENT OF INFLAMMATORY, INNATE IMMUNE RESPONSE OR AUTOIMMUNE DISORDERS | UNIV FLORIDA (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12370193-B2 | Method of inhibiting TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-07-29 | — | — | US | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118684644-A | Eupatilin derivative containing piperazine structure and preparation method and application thereof | 南阳医学高等专科学校 | 2024-09-24 | — | — | CN | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024059333-A1 | COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2023-05-30 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-110615774-B | Benzyl piperazine compound with anti-inflammatory activity, preparation method and medical application | 安徽中医药大学 | 2022-11-11 | — | — | CN | disclosed |
| US-11447468-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220117965-A1 | METHOD OF INHIBITING TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2022-04-21 | — | — | US | disclosed |
| CN-112191273-B | High-entropy coordination polymer catalyst for oxygen production by electrolyzing water and preparation method and application thereof | 中国科学技术大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3946349-A1 | METHOD OF INHIBITING TREM-1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3921038-A1 | IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3481824-B1 | 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| CN-109563092-B | 2-phenylimidazo [4,5-B ] pyridin-7-amine derivatives useful as inhibitors of the activity of the mammalian tyrosine kinase ROR1 | 坎塞拉有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-11008318-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2021-05-18 | — | — | US | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3573987-B1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-03-10 | — | — | EP | disclosed |
| CN-112191273-A | High-entropy coordination polymer catalyst for oxygen production by electrolyzing water and preparation method and application thereof | 中国科学技术大学 | 2021-01-08 | — | — | CN | disclosed |
| WO-2020206213-A1 | METHOD OF INHIBITING TREM-1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| CN-106966978-B | Amide compound and preparation method and application thereof | 北京化工大学 | 2020-06-26 | — | — | CN | disclosed |
| CN-110615774-A | Benzyl piperazine compound with anti-inflammatory activity, preparation method and medical application | 安徽中医药大学 | 2019-12-27 | — | — | CN | disclosed |
| CN-105085429-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| WO-2019177997-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3481824-A1 | 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | Kancera AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3468953-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109438483-A | A kind of hybrid material preparation method of fluorescence temperature measuring appliance | 南京晓庄学院 | 2019-03-08 | — | — | CN | disclosed |
| CN-109438484-A | A kind of hybrid material for temperature meter | 南京晓庄学院 | 2019-03-08 | — | — | CN | disclosed |
| CN-109369688-A | A kind of application of material | 南京晓庄学院 | 2019-02-22 | — | — | CN | disclosed |
| CN-108456217-B | Fluorescent temperature measurer hybrid material, preparation method and application | 南京晓庄学院 | 2019-01-25 | — | — | CN | disclosed |
| CN-109111415-A | A kind of dendrobium nobile alcaloid-derivatives, preparation method and medical usage | 安徽中医药大学 | 2019-01-01 | — | — | CN | disclosed |
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| WO-2018011138-A1 | 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| CN-107011287-A | The ketone derivatives of 2 piperazine, 1 base 4H, 1,3 benzothiazines 4 and its purposes for treating mammalian infections | 洛桑联邦理工学院(EPFL) | 2017-08-04 | — | — | CN | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-105399698-A | Aromatic heterocyclic derivatives and applications of aromatic heterocyclic derivatives in medicines | GUANGDONG HEC PHARMACEUTICAL | 2016-03-16 | — | — | CN | disclosed |
| WO-2016034134-A1 | HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-10 | — | — | WO | disclosed |
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| CN-105175409-A | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY LLC | 2015-12-23 | — | — | CN | disclosed |
| CN-103502225-B | As the triazolyl piperazine be substituted and the triazolyl piperidine derivative of gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-105085429-A | Heteroaromatic derivative and application thereof to medicament | GUANGDONG HEC PHARMACEUTICAL | 2015-11-25 | — | — | CN | disclosed |
| WO-2015161830-A1 | HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-29 | — | — | WO | disclosed |
| EP-2923703-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8993760-B2 | Rock inhibitors and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987276-B2 | Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| CN-102300844-B | Sulfamoyl-phenyl-ureidobenzamidine derivatives as antimalarial agents | 4SC AG | 2015-03-11 | — | — | CN | disclosed |
| EP-2688874-B1 | 1,3,5-SUBSTITUTED 3-PIPERAZINE- OR 3-PIPERIDINE-1,2,4-TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | JANSSEN PHARMACEUTICALS INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| CN-102573485-B | triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2014-11-26 | — | — | CN | disclosed |
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8796264-B2 | 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| US-8722883-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2688874-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20140011816-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-09 | — | — | US | disclosed |
| CN-103502225-A | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators | JANSSEN PHARMACEUTICALS INC | 2014-01-08 | — | — | CN | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA R&D ALDERLY PARK (GB) | 2013-08-08 | — | — | US | disclosed |
| CN-103221399-A | 2-piperazin-1-yl-4H-1, 3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections | ECOLE POLYTECH | 2013-07-24 | — | — | CN | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-8410123-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8338595-B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| CN-102762549-A | Phthalazinone derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2012126984-A1 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-102573485-A | Triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2012-07-11 | — | — | CN | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-8173682-B2 | Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2440050-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20120046270-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2012019430-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-8114875-B2 | Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| CN-102300844-A | Sulfamoyl-phenyl-ureidobenzamidine derivatives as antimalarial agents | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2391601-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-1893207-B1 | USE OF SUBSTITUTED PIPERAZINE DERIVATIVES AND MORPHOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-1893207-B1 | USE OF SUBSTITUTED PIPERAZINE DERIVATIVES AND MORPHOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010144338-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| WO-2010094695-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010086177-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| CN-1993361-B | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP | 2010-05-26 | — | — | CN | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167490-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Korea Research Institute Of Chemical Technology (KR) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2010026262-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2010001169-A2 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | WO | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | US | disclosed |
| US-7495022-B2 | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2009-02-24 | — | — | US | disclosed |
| WO-2009003999-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008153325-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008108957-A2 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-7419995-B2 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| CN-101193867-A | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole libraries | OSI PHARM INC (US) | 2008-06-04 | — | — | CN | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1893207-A1 | USE OF SUBSTITUTED PIPERAZINE DERIVATIVES AND MORPHOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1828146-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1809624-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1993361-A | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1765823-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006024823-A9 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| EP-1761520-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006133784-A1 | USE OF SUBSTITUTED PIPERAZINE DERIVATIVES AND MORPHOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060264419-A1 | Substituted pyrazoles | MERCK PATENT GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006066885-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| EP-1334972-B1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| WO-2006024823-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006009741-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1609789-A1 | UREIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005121147-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| CN-1210274-C | Piperazine and piperidine derivatives | VERTEX PHARMA (US) | 2005-07-13 | — | — | CN | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-6833372-B2 | A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups | PFIZER, INC. | 2004-12-21 | — | — | US | disclosed |
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004080979-A1 | NOVEL 3-(2-AMINO-4-PYRIMIDINYL)-4-HYDROXYPHENYL KETONE DERIVATIVES | LG LIFE SCIENCES LTD. (KR) | 2004-09-23 | — | — | WO | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1441728-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087071-A1 | SULFONAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087066-A1 | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | SK CHEMICALS, CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003068769-A1 | NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH) | PFIZER INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1334972-A1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER INC. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| WO-2003037338-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-08 | — | — | WO | disclosed |
| CN-1404477-A | Piperazine and piperidine derivatives | VERTEX PHARMA (US) | 2003-03-19 | — | — | CN | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6479514-B1 | FOR THE CONTROL OF HELICOBACTER BACTERIA IN INFECTED PATIENTS | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| CN-1087737-C | Dihygropyridine derivatives as bradykinin antagonists | PFIZER (US) | 2002-07-17 | — | — | CN | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-0777653-B1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-1086094-A1 | QUINOLINE-AMINOMETHYL-PYRIDYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999061438-A1 | QUINOLINE-AMINOMETHYL-PYRIDYL DERIVATIVES WITH ANTI-HELICOBACTER ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-02 | — | — | WO | disclosed |
| EP-0925302-A1 | PALLADIUM CATALYZED INDOLIZATION | Merck & Co., Inc. (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0922042-A1 | NOVEL PIPERAZINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5859011-A | Dihydropyridine derivatives as bradykinin antagonist | PFIZER INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998006725-A1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998006715-A1 | NOVEL PIPERAZINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| CN-1156449-A | Dihygropyridine derivatives as bradykinin antagonists | PFIZER (US) | 1997-08-06 | — | — | CN | disclosed |
| EP-0777653-A1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006083-A1 | 2-(PIPERAZINYL-1-CARBONYLMETHYL)-1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996006082-A1 | DIHYDROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| US-4582833-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4122178-A | ANALGESICS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1978-10-24 | — | — | US | disclosed |
| US-4122178-A | ANALGESICS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | HPGD 4536/4885SIGMAR1 3483/4885CYP2D6 3447/4885 |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HPGD 346/4885SIGMAR1 3835/4885CYP2D6 516/4885 |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | HPGD 555/4885SIGMAR1 3546/4885CYP2D6 4384/4885 |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | HPGD 667/4885SIGMAR1 439/4885CYP2D6 137/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HPGD 1030/4885SIGMAR1 2433/4885CYP2D6 2024/4885 |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | HPGD 1630/4885SIGMAR1 2819/4885CYP2D6 958/4885 |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | HPGD 1190/4885SIGMAR1 1407/4885CYP2D6 378/4885 |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | MKI67, CCNA1, CCNT1 | HPGD 2083/4885SIGMAR1 693/4885CYP2D6 451/4885 |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885SIGMAR1 2500/4885CYP2D6 921/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885SIGMAR1 2500/4885CYP2D6 921/4885 |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | HPGD 1863/4885SIGMAR1 822/4885CYP2D6 1807/4885 |
| US-11447468-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | HPGD 555/4885SIGMAR1 3546/4885CYP2D6 4384/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | HPGD 3430/4885SIGMAR1 3966/4885CYP2D6 3334/4885 |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | HPGD 2890/4885SIGMAR1 1955/4885CYP2D6 807/4885 |
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | CHAT, DCX, GAP43 | HPGD 504/4885SIGMAR1 4523/4885CYP2D6 4764/4885 |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | HPGD 440/4885SIGMAR1 346/4885CYP2D6 1297/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | HPGD 1961/4885SIGMAR1 4605/4885CYP2D6 1803/4885 |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | RORB, RORA, RORC | HPGD 2392/4885SIGMAR1 805/4885CYP2D6 1314/4885 |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | HPGD 261/4885SIGMAR1 557/4885CYP2D6 1218/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HPGD 283/4885SIGMAR1 2155/4885CYP2D6 2336/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | HPGD 1383/4885SIGMAR1 1921/4885CYP2D6 2197/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | HPGD 1042/4885SIGMAR1 1202/4885CYP2D6 505/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | HPGD 1334/4885SIGMAR1 44/4885CYP2D6 1259/4885 |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | DNMT1, DNMT3A, DNMT3B | HPGD 3170/4885SIGMAR1 551/4885CYP2D6 705/4885 |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | DNMT1, DNMT3A, DNMT3B | HPGD 3170/4885SIGMAR1 551/4885CYP2D6 705/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | HPGD 261/4885SIGMAR1 557/4885CYP2D6 1218/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | HPGD 427/4885SIGMAR1 1374/4885CYP2D6 338/4885 |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | HPGD 891/4885SIGMAR1 2985/4885CYP2D6 4295/4885 |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | HPGD 74/4885SIGMAR1 4723/4885CYP2D6 3990/4885 |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | HPGD 74/4885SIGMAR1 4723/4885CYP2D6 3990/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HPGD 346/4885SIGMAR1 3835/4885CYP2D6 516/4885 |
| US-20060264419-A1 | Substituted pyrazoles | HTR3A, HTR1A, HTR1D | HPGD 1370/4885SIGMAR1 23/4885CYP2D6 316/4885 |
| US-12370193-B2 | Method of inhibiting TREM-1 | DAPK3, DAPK1, GPR3 | HPGD 3572/4885SIGMAR1 1563/4885CYP2D6 3656/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | HPGD 555/4885SIGMAR1 3546/4885CYP2D6 4384/4885 |
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | HPGD 515/4885SIGMAR1 2866/4885CYP2D6 4847/4885 |
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | HPGD 3451/4885SIGMAR1 2301/4885CYP2D6 1028/4885 |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | PDE4A, PDE4B, PDE3A | HPGD 828/4885SIGMAR1 2433/4885CYP2D6 651/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | HPGD 372/4885SIGMAR1 1938/4885CYP2D6 2191/4885 |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | MKI67, CCNA1, CCNI | HPGD 523/4885SIGMAR1 2202/4885CYP2D6 2549/4885 |
| US-11008318-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | HPGD 3421/4885SIGMAR1 2137/4885CYP2D6 1772/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | HPGD 1228/4885SIGMAR1 216/4885CYP2D6 331/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | HPGD 667/4885SIGMAR1 439/4885CYP2D6 137/4885 |
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | NR5A1, NR3C1, NR1H3 | HPGD 2700/4885SIGMAR1 437/4885CYP2D6 3433/4885 |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | HPGD 413/4885SIGMAR1 3729/4885CYP2D6 136/4885 |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | HPGD 261/4885SIGMAR1 557/4885CYP2D6 1218/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | HPGD 555/4885SIGMAR1 3546/4885CYP2D6 4384/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | HPGD 1182/4885SIGMAR1 3279/4885CYP2D6 2737/4885 |
| US-20260083728-A1 | COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA | CLIC1, AOC2, CFTR | HPGD 3956/4885SIGMAR1 179/4885CYP2D6 767/4885 |
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | BPGM, TBC1D5, TBC1D15 | HPGD 730/4885SIGMAR1 3391/4885CYP2D6 2513/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | HPGD 299/4885SIGMAR1 506/4885CYP2D6 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.